The two largest hemodialysis service providers, Fresenius Medical Care (NYSE: FMS ) and DaVita HealthCare Partners (NYSE: DVA )
, may have a lot in common, but the performance of their shares is not
one of them. Over the past year, DaVita has a 10% lead on on Fresenius
and that lead only increases at the two-year (roughly 60%), and
five-year (nearly 120%) marks.
Though the operating margins have been similar, DaVita has
significantly outgrown Fresenius over the past decade and generated more
free cash flow as a percentage of revenue. Better still, DaVita's
HealthCare Partners business looks like a "right place, right time,
right idea" operation that can benefit from a growing focus on basing
health care spending on outcomes, not procedures. Considering DaVita's
growth potential, the shares may yet be as much as 20% undervalued
today.
Continue here:
Can DaVita HealthCare Partners Inc's Run Last?
Showing posts with label DaVita. Show all posts
Showing posts with label DaVita. Show all posts
Monday, April 7, 2014
Wednesday, April 2, 2014
The Motley Fool: Can Fresenius Medical Care AG & Co. Get Past Medicare Reimbursement Issues?
When Medicare plays a major role in a company's business model there always seem to be challenges. Such is the case for Fresenius Medical Care (NYSE: FMS )
. While the company's strong global share in dialysis equipment and
strong share in North American dialysis services ought to be a strong
positive in the company's favor, the difficult reimbursement environment
has created challenges and uncertainties in the company's model. Though
there is a significant global growth in the number of patients with
end-stage renal disease, Fresenius Medical Care can't afford to drop the
ball when it comes to careful expense management.
Read more here:
Can Fresenius Medical Care AG & Co. Get Past Medicare Reimbursement Issues?
Read more here:
Can Fresenius Medical Care AG & Co. Get Past Medicare Reimbursement Issues?
Labels:
Amgen,
Baxter,
DaVita,
Fresenius Medical Care,
The Motley Fool
Tuesday, November 27, 2012
Investopedia: Will Baxter Go For Gambro?
When
real news fade, rumors seem to crop up a little more readily. In the
case of the rumor that Baxter
(NYSE:BAX)
is arranging a bid for Gambro,
however, there's a little more credibility than usual. Baxter has
long wanted Gambro, and the combination would make sense in a
med-tech market where growth is increasingly hard to come by.
For the full article please continue here:
http://www.investopedia.com/
Labels:
Baxter,
DaVita,
Fresenius,
Gambro,
Investopedia,
NxStage Medical
Subscribe to:
Posts (Atom)